Platelet-derived growth factor receptor alpha (PDGFRa) and c-Kit are receptor tyrosine kinases. Both are targets of the tyrosine kinase inhibitor imatinib mesylate which is approved for treatment of some cancers. In order to assess the role of PDGFRa and c-Kit in malignant peripheral nerve sheath tumours (MPNST) we examined human tumours for structural alterations, protein and ligand expression. We investigated 34 MPNST, 6 corresponding plexiform neurofibromas (pNF) and 1 MPNST cell culture from 31 patients for mutations and polymorphisms in PDGFRA (exon 2-21) and KIT (exon 9, 11, 13, 17). PDG-FRA was amplified in seven tumours from six patients and MPNST cell culture S462. KIT was amplified in five tumours from four patients and in the cell culture. Two MPNST carried somatic PDGFRA mutations in exons coding for the extracellular domain. In addition we detected several polymorphisms in PDGFRA. No point mutations or polymorphisms were detected in the four KIT exons analysed. PDGFRa expression was present in 21 of 28 MPNST patients (75%) and the MPNST cell culture. Expression analysis of PDGFRa ligands in MPNST and neurofibromas revealed that PDGF-A was more widely expressed than PDGF-B. Focal c-Kit expression was detected in 2 of 29 (7%) MPNST patients. Imatinib treatment of MPNST cell culture S462 exerted a growth inhibitory effect and prevented PDGF-AA induced PDGFRa phosphorylation. In summary, PDGFRA, PDGF and KIT dysregulation as well as growth inhibition of cell culture S462 by imatinib may suggest that MPNST patients benefit from treatment with imatinib.
Introduction
Malignant peripheral nerve sheath tumours (MPNST) are very aggressive tumours with poor prognosis. Approximately half of the MPNST occur in the setting of Neurofibromatosis type 1 (NF1), a hereditary tumour syndrome with an incidence of 1:3500 (1) . MPNST in NF1 patients is the major cause for reduced life expectancy with only 21% of NF1 patients surviving longer than 5 years after diagnosis of MPNST (2) .
The NF1 gene on chromosome 17q11.2 encodes the large protein neurofibromin, which acts as negative regulator of ras. Functional neurofibromin is lost in NF1 associated nerve sheath tumours. However, not much is known about additional molecular aberrations underlying transformation or malignant progression of nerve sheath tumours. However, TP53 and CDKN2A have been shown to harbour mutations in a subgroup of MPNST (3) (4) (5) . In addition, gene amplification and increased transcription of EGFR have been detected in MPNST (6, 7) . MPNST in NF1 patients frequently arise from malignant progression of plexiform neurofibromas (pNF). Dermal neurofibromas (dNF), which develop in nearly all NF1 patients, virtually have no risk of malignant transformation. With the exception of NF1 loss, little is known about genetic aberrations in neurofibromas.
We have recently demonstrated higher expression of platelet-derived growth factor receptor alpha (PDGFRa) in MPNST than in benign nerve sheath tumours (8) . Because ligands of PDGFRa are powerful mitogens for Schwann cells (9) , the PDGF system might contribute to malignant progression of nerve sheath tumours. The PDGF system is complex with two receptor genes forming three receptor types (PDGFRa and PDGFRb homodimers and PDGFRab heterodimers). These receptors may bind ligands encoded by four genes building at least five different dimers (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD) with different receptor-binding specificities (10) . Expression of c-Kit and its ligand stem cell factor was found in MPNST cell cultures (11, 12) and c-Kit expression was documented in an MPNST (13) .
PDGFRa and c-Kit belong to the type III subfamily of receptor tyrosine kinases. Both have been reported to be strongly expressed and/or mutated in gastrointestinal stromal tumours (GIST) and gliomas (14, 15) .
PDGFRA and KIT have attracted special attention since it became evident that their protein products were among the tyrosine kinases inhibited by imatinib mesylate (GlivecÒ, STI571). Imatinib treatment yields high response rates in patients with GIST and chronic myeloid leukemia (CML) (16, 17) . The major target of imatinib in GIST is mutant cKit, whereas the inhibited kinase in CML is the Bcr-Abl fusion protein. Successful treatment with imatinib has also been reported for patients with dermatofibrosarcoma protuberans. This disease is characterized by a chromosomal translocation leading to overexpression of PDGF-B, which is bound by all 3 PDGF receptor types (18) .
Our previous findings of increased PDGFRa levels in MPNST led us to examine MPNST for activating mutations or amplifications. Activation of PDGFRa and c-Kit would render MPNST attractive candidates for imatinib treatment. Since there are only limited treatment options for MPNST patients new treatment possibilities are required.
Materials and methods
Tumour tissue, DNA and RNA extraction Tumour samples were collected from University Hospital Eppendorf (Hamburg, Germany), Robert-Rössle-Hospital (Berlin, Germany), Otto-vonGuericke-University (Magdeburg, Germany) and Charité University Hospital (Berlin, Germany). The study contained 40 nerve sheath tumours (34 MPNST and 6 pNF) from 31 patients and MPNST cell culture S462, which was established from MPNST 24472 (19) . Twenty-six patients were diagnosed with NF1. Following initial diagnosis in local neuropathologies, all tumour samples were reviewed by the same pathologist (A.F.O.). Histopathological examination was based on the modified FNCLCC system (20) . Eleven tumour samples have already been analysed for gene expression profiles (6) . Before extraction of DNA, RNA and protein tumour samples were examined by histology to exclude contaminating non-tumourous portions. In case of frozen material DNA and RNA was extracted using TRIzol reagent from Invitrogen (Karlsruhe, Germany). DNA extraction from paraffin embedded material was carried out according to the QIAamp DNA Mini Kit protocol (Qiagen, Hilden, Germany). Four MPNST (24626, 24772, 24776 and 24324) contained adjacent pNF tissue. DNA from pNF and MPNST areas were separately extracted. A c-Kit positive GIST was kindly provided by Prof. Gottschalk (Hamburg) and served as positive control for immunohistochemistry. Microdissection of skeletal muscle and vascular endothelial cells was performed with two cases (24748 and 24772) because blood was not available. The PALM Laser Microbeam System (Bernried, Germany) was employed to dissect $2000 cells from paraffin sections stained with toluidine blue as described previously (21) . The investigations were carried out with the informed consent of the patients.
SSCP and sequencing
Electrophoresis of PCR products of PDGFRA exon 2-21 and KIT exon 9, 11, 13, 17 was performed on polyacrylamid gels applying 500 V and 6 mA for 18 h. All PCR products showing a mobility shift were confirmed by an independent PCR and compared with PCR products of corresponding normal tissue (blood or microdissected normal cells). Aberrantly migrating SSCP bands were excised and the DNA was extracted. After reamplification, PCR products were sequenced bidirectionally on a semiautomated sequencer (model 377; Applied Biosystems, Foster City, CA). Sequences were compared to PDGFRA NM_006206 and KIT X06182. Primer sequences are compiled in Table I . Amplification and gel conditions are available on request.
Gene amplification analysis by real-time PCR Quantitative real-time PCR was performed with SYBR green I (1:5000 dilution, Molecular Probes, The Netherlands) using the ABI Prism 7700 Sequence Detection System (Applied Biosystems). PCR products of the target genes KIT (Exon 17, PCR product of 185 bp) and PDGFRA (Exon 21, PCR product of 148 bp) were compared to the reference gene DES (Exon 8, PCR product of 180 bp) on chromosome 2q35 encoding desmin. This region appears not to have gains of chromosomal material in MPNST (22) . Primer sequences are given in Table I . PCR efficiency, determined by serial dilution of DNA, demonstrated similar results for target and reference genes. All samples were analysed in duplicate in 25 ml reaction mixes containing 1.25 U of Platinum Taq DNA Polymerase (Invitrogen). Amplification conditions are available on request. Evaluation of data were performed using the DDCt method: DDCt ¼ DCt tumour DNA À DCt blood DNA. DCt (threshold cycles) is the Ct of the reference gene minus the Ct of the target gene. Fold increase of the target genes (PDGFRA and KIT) was calculated by 2 (DDCt) and values of !1.7 were defined PDGFRA and KIT dysregulation and mutation as gene amplification. Tumours conspicuous for gene amplification were verified in an independent PCR run. DNAs from glioblastomas with known PDGFRA amplification served as positive controls (15) .
RT-PCR analysis RT of 2 mg DNA free RNA was achieved with the SuperScriptÔ First-Strand Synthesis System (Invitrogen). PCR were performed in a volume of 20 ml containing cDNA transcripts equivalent to 45 ng RNA. For the detection of large deletions in PDGFRA 10 MPNST (21852, 24784, 26580, 26582, 26584, 26586, 26588, 26592, 24472, 21914) and the cell culture S462 were analysed using four overlapping primer pairs covering the whole coding region of PDGFRA. Primer sequences are given in Table I . PCR fragments were separated on 1.5% agarose gels allowing size differences of 50 bp to be visualized. For semi-quantitative ligand determination 35 PCR cycles were performed for PDGFA and PDGFB, and 32 cycles were performed for the reference gene RPS3. Amplification conditions are available on request.
Immunohistochemistry and scoring
Immunohistochemistry was performed with a Ventana BenchmarkÔ automate (Ventana, Strasbourg, France). The antibodies against PDGFRa (C-20, dilution 1:100) and PDGF-A (N-30, dilution 1:50) were obtained from Santa Cruz Biotechnology (Heidelberg, Germany). The c-Kit antibody (A4502, dilution 1:400) was obtained from Dako (Hamburg, Germany). Antigen retrieval was enhanced by heating. Primary antibodies were incubated for 30 min at 40 C. Negative controls without primary antibodies were carried out and did not produce signals. Scoring was performed according to the percentage of positive cells: 55% was classified as negative (À), 6-100% was classified as positive. Positive cells (6-30%) were scored with þ, 31-60% with þþ, 460% with þþþ. A repeated test (blinded) gave similar results.
) per well were seeded on Permanox chamberslides (Nunc, Wiesbaden, Germany). Cells were fixed with acetone the following day. The same antibodies used for immunohistochemistry were applied in a 1:50 dilution. Incubation of primary antibodies was performed for 2 h at room temperature. Visualization was performed with Cy3-(Dianova, Hamburg, Germany) or Alexa488-(Invitrogen) conjugated anti-rabbit antibodies (dilution 1:100). Negative controls without primary antibodies were carried out and did not produce signals.
Western blot
Tumour lysates were heat denaturated and loaded on to 7.5% acrylamide gels for subsequent protein separation. After transfer of proteins to nitrocellulose membranes, the membranes were blocked in 3% non-fat dry milk with 0.05% Tween-TBS for 1 h and incubated overnight at 4 C with anti-PDGFRa antibody (C-20, dilution 1:200). After washing, the membranes were incubated for 1 h with biotin-conjugated second antibodies, washed and incubated 1 h with ExtrAvidin from Sigma (dilution 1:2000) . Visualization was performed with ECL (Amersham Biosciences, Freiburg, Germany). Lysates were adjusted to b-actin expression levels which were determined with the anti-b-actin antibody AC-15 (dilution 1:6.000) from Sigma (Munich, Germany). Phosphorylation was detected with anti-p-Tyr (PY99, dilution 1:10.000) from Santa Cruz Biotechnology.
Cell culture assays During imatinib inhibition the MPNST cell culture S462 (518 passages) was maintained in DMEM Glutamax-I with 5% FBS from Invitrogen (Karlsruhe, Germany). Imatinib mesylate was kindly provided by Novartis Pharma AG (Basel, Switzerland) and dissolved in dimethyl sulphoxide (DMSO). Cells (2 Â 10 3 ) were seeded in 300 ml medium into 24 well plates and were allowed to adhere. Imatinib was added in 100 ml to final concentrations of 2 mM and 10 mM with no more than 0.1% DMSO. Negative controls contained 0.1% DMSO only. The 300 ml of medium containing respective imatinib or DMSO concentrations were exchanged on day 3 and 5. Cell proliferation was evaluated on day 4 and 7 post-imatinib treatment with the CellTiter 96 AQueous One Solution Cell Proliferation Assay from Promega (Mannheim, Germany) by measurement of absorbance at 490 nm. The experiments were performed in duplicate and repeated thrice with comparable results.
Imatinib effect on PDGFRa phosphorylation was determined in 6 well plates in duplicates. Cells (5 Â 10 5 ) were seeded per well in DMEM with 10% FBS. The next day medium was changed to serum-free DMEM. After 24 h imatinib or DMSO was added and cells were incubated for 30 min. Cells were then stimulated with PDGF-AA (50 ng/ml) for 10 min, washed with phosphatebuffered saline (PBS), scraped, centrifuged and resuspended in lysis buffer [1% Triton X-100, 100 mM NaCl, 50 mM Tris-HCl (pH 7.5) and 5 mM EDTA]. Protease inhibitor cocktail (Roche, Penzberg, Germany) and phosphatase inhibitor cocktail 2 (Sigma, Saint Louis, Missouri) were added.
Stimulation with PDGF-AA and PDGF-BB (Oncogene, San Diego, CA) was performed in 6 well plates with 50 ng PDGF per ml serum-free DMEM for 48 h. Each well contained 10 5 cells seeded in DMEM with 10% FBS. The next day medium was switched to serum-free DMEM. Cell line ST88-14 and DBTRG (kindly provided by A. Kurtz and E. Elstner) were cultured in DMEM Glutamax-I with 10% FBS.
Results

Mutations and polymorphisms
We investigated 34 MPNST, 6 pNF and 1 MPNST cell culture from 31 patients for PDGFRA mutations (exon 2-21) and KIT mutations (exon 9, 11, 13, 17). Because KIT mutations in GIST mostly occur in exon 9 and 11 but also in exon 13 and 17 we restricted our analysis to these four exons (23) . We detected somatic PDGFRA mutations in 2 MPNST ( Figure 1A and B) . MPNST 24748 had a mutation in exon 4 (CCT4TCT, codon 130) leading to the non-conservative amino acid exchange from proline to serine. MPNST 24740 harboured a somatic mutation in exon 10 (GTC4GCC, codon 469) leading to an exchange from valine to alanine.
Because a transforming PDGFRa deletion mutant (loss of exon 8 and 9) was reported in a glioblastoma (24) we examined PDGFRA cDNA in order to detect large deletions that would not be recognized by SSCP. Analysis of 10 MPNST and cell culture S462 did not reveal large deletions (data not shown).
We found six different single nucleotide polymorphisms in PDGFRA which are listed in Table II Gene amplification of PDGFRA and KIT PDGFRA and KIT amplification was investigated by real-time PCR. Eight samples (seven solid tumours and cell culture S462) from six patients showed PDGFRA amplification by a factor of 1.8 or more relative to the normal gene dose. KIT amplifications were detected in six samples (five tumours and cell culture S462) from four patients. Five samples (24472, 24784, 21914, 22318, cell culture S462) showed amplification of both, PDGFRA and KIT. Gene amplification results are summarized in Table III . Immunohistochemistry revealed focal c-Kit expression in 2 MPNST ( Figure 1D ). C-Kit positive mast cells within the tumours and a c-Kit expressing GIST served as controls.
Expression of receptors PDGFRa and c-Kit
Expression of growth factors PDGFA and PDGFB
In order to examine PDGFRa ligand expression in neurofibromas and MPNST we performed RT-PCR for PDGFA and PDGFB in 5 dNF, 3 pNF, 8 MPNST and 2 MPNST cell cultures and the glioblastoma cell line DBTRG. PDGFA was expressed in most tumours whereas PDGFB was detected in only 1 pNF but the majority of MPNST (Figure 3) . Table III .
Inhibition of MPNST cell culture proliferation and phosphorylation of PDGFRa by imatinib
The inhibitory effect of imatinib was tested with concentrations of 2 and 10 mM. Use of 2 mM imatinib led to an 11% reduction in proliferation on day 4 and a reduction of 39% on day 7 as compared to untreated control cells. The effect of 10 mM imatinib was more pronounced with 58% inhibition on day 4 and 66% on day 7 post-exposure ( Figure 4A ). This corresponds to a biologic IC 50 of 510 mM. Next, we evaluated if concentrations of 2 mM and 10 mM imatinib would inhibit ligand induced phosphorylation of PDGFRa. In fact, both imatinib concentrations prevented PDGF-AA induced phosphorylation in S462 cells which corresponds to a pharmacologic IC 50 52 mM ( Figure 4B) .
Stimulation with PDGF-AA and PDGF-BB increased proliferation of S462 cells under serum-free conditions by a factor of four in comparison to the untreated controls (data not shown).
Discussion
This study is the first to demonstrate molecular aberrations of receptor tyrosine kinase genes PDGFRA and KIT in MPNST. We detected gene amplification of PDGFRA in 6 and somatic point mutations in 2 of 31 patients with MPNST. Structural alterations of PDGFRA were therefore present in 8 of 31 (26%) patients with MPNST. The 2 point mutations localized to exon 4 and exon 10 of PDGFRA, which encode parts of the extracellular domain of PDGFRa. PDGFRA exon 10 corresponds to KIT exon 9 which is the second most mutated KIT exon in GIST (23) . We found valine substituted by alanine in codon 469. This valine, located in the Ig-like domain of the receptors, is conserved in c-Kit and corresponds there to codon 459. Mutations in the extracellular domain may modulate ligand-binding and dimerization, thereby indirectly influencing tyrosine kinase activity. Finally, mutations of PDGFRA in MPNST occur as frequent as EGFR amplifications, which have also been found in 26% of MPNST (7) . Other frequent alterations in MPNST include NF1, CDKN2A and TP53 deletions and/or mutations (5, 7, 19, 26) . Until today not many tumour entities with mutations in PDGFRA have been described. Recently it was shown, that a subset of about 35% of GISTs lacking KIT mutations carried mutations in PDGFRA (27, 28) indicating that either KIT or PDGFRA aberrations contribute to the development of these tumours. We detected 7 allelic variants of PDGFRA present in both, tumour and reference tissues. Three of them led to an amino acid exchange and one to a truncated protein. The 478Pro variant has been described before and functional analysis revealed no constitutive phosphorylation like 2 PDGFRa gain-of-function mutants (25, 28) . We found a variant of PDG-FRA with an 18 bp deletion resulting in a truncated protein lacking the 6 amino acids SWLKNN in a single patient (Table II) . This deletion is located in the extracellular Ig-like domain IV and may, therefore, modulate ligand-binding. Protein extracts for western blotting were available from 5 MPNST patients. Three samples showed expression of PDGFRa, 2 of which were detected with amplification. Two samples with weak PDGFRa expression were derived from one patient with, and one without, gene amplification. With the exception of pNF 22476, all tumours with KIT amplification also exhibited PDGFRA amplification. Notably, PDGFRA and KIT map next to each other with a distance of 359 kb on the chromosomal segment 4q12. Thus, the amplicon in the majority of the MPNST in our series contains more than one gene. Amplicons containing several genes have been described previously such as the frequent amplicons on chromosomal segment 12q13-q15 in glioblastoma containing MDM2, SAS, CDK4 and in some cases also GADD153, GLI, RAP1B, A2MR and IFNG (30) . In MPNST the amplification of both PDGFRA and KIT may have profound effects on signal transduction. However, our observation of higher frequency of PDGFRA aberrations and stronger expression of PDGFRa may suggest that this gene provides a major selective advantage for MPNST tumour cells and that KIT, due to infrequent PDGFRA and KIT dysregulation and mutation expression of the protein, may be co-amplified as an 'innocent bystander'. Because point mutations in PDGFRA appear to be infrequent in MPNST we suggest that an autocrine loop of the PDGF system supports proliferation and angiogenesis. We could show, that expression of PDGFR ligands PDGF-A and PDGF-B is common to nerve sheath tumours. PDGFA was more widely expressed than PDGFB especially in neurofibromas. Similar mechanisms are known to play a role in gliomas (31, 32) . In addition to an autocrine loop, paracrine stimulation of the PDGF system may also contribute to tumour proliferation because fibroblasts are known to be a source for PDGF. There is evidence for a direct link between NF1 and PDGF. It was shown that Schwann cells derived from Nf1À/À mice expressed PDGFB which was absent in Nf1þ/þ mice (33) .
Patients with GIST respond to treatment with imatinib, an inhibitor of the protein tyrosin kinase c-Kit (16). Imatinib does not selectively inhibit c-Kit but also interferes with other receptor tyrosine kinases such as PDGFRa (34, 35) . We therefore analysed growth of MPNST cells at imatinib concentrations of 2 and 10 mM employing cell culture S462, which was shown to harbour loss of heterozygosity in genes encoding neurofibromin, p53 and p16 (19) . S462 showed a dosedependent reduction of cell growth in vitro ( Figure 4A ). Ligand induced phosphorylation of PDGFRa was completely inhibited at both concentrations of imatinib ( Figure 4B ). The effect of imatinib on PDGFRa positive tumour cells has recently been shown in ovarian cancer cells. Only PDGFRa positive cell cultures were inhibited while cell lines lacking PDGFRa expression were not affected (36) . In patients, a mean plasma concentration of up to 4.6 mM imatinib after oral administration of 400 mg (1.46 mM after 24 h) has been reported (17) . Therefore, the concentration of imatinib inhibiting MPNST cell culture is similar to that in patient plasma. Further support for the potential sensitivity to imatinib is derived from the observation, that a majority of MPNST patients with PDGFRA amplification also exhibit amplification of KIT, although the latter seems not to be strongly expressed in tumour cells. However, c-Kit positive mast cells within the tumour are thought to contribute to its development (37) . Therefore, MPNST carry at least two targets of imatinib. These data may indicate that patients with MPNST benefit from imatinib treatment.
In conclusion, we describe frequent mutations of PDGFRA in MPNST often associated with coamplification of KIT. In vitro growth of an MPNST cell line could be inhibited by the tyrosin kinase inhibitor imatinib which is known to target both PDGFRa and c-Kit. PDGFRa should therefore be considered as candidate for targeted therapy of MPNST.
